Logo image of KIN.BR

KINEPOLIS (KIN.BR) Stock Fundamental Analysis

EBR:KIN - Euronext Brussels - BE0974274061 - Common Stock - Currency: EUR

38.1  -0.5 (-1.3%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to KIN. KIN was compared to 44 industry peers in the Entertainment industry. While KIN is still in line with the averages on profitability rating, there are concerns on its financial health. KIN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

KIN had positive earnings in the past year.
In the past year KIN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: KIN reported negative net income in multiple years.
Of the past 5 years KIN 4 years had a positive operating cash flow.
KIN.BR Yearly Net Income VS EBIT VS OCF VS FCFKIN.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

1.2 Ratios

KIN has a Return On Assets of 3.20%. This is in the better half of the industry: KIN outperforms 65.00% of its industry peers.
Looking at the Return On Equity, with a value of 19.41%, KIN is in the better half of the industry, outperforming 77.50% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 6.48%, KIN is in the better half of the industry, outperforming 67.50% of the companies in the same industry.
Industry RankSector Rank
ROA 3.2%
ROE 19.41%
ROIC 6.48%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KIN.BR Yearly ROA, ROE, ROICKIN.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

1.3 Margins

The Profit Margin of KIN (6.29%) is better than 70.00% of its industry peers.
KIN's Profit Margin has been stable in the last couple of years.
KIN has a Operating Margin of 13.74%. This is amongst the best in the industry. KIN outperforms 85.00% of its industry peers.
In the last couple of years the Operating Margin of KIN has remained more or less at the same level.
The Gross Margin of KIN (23.56%) is worse than 87.50% of its industry peers.
In the last couple of years the Gross Margin of KIN has remained more or less at the same level.
Industry RankSector Rank
OM 13.74%
PM (TTM) 6.29%
GM 23.56%
OM growth 3YN/A
OM growth 5Y0.72%
PM growth 3YN/A
PM growth 5Y-1.43%
GM growth 3YN/A
GM growth 5Y-0.65%
KIN.BR Yearly Profit, Operating, Gross MarginsKIN.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

1

2. Health

2.1 Basic Checks

KIN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
KIN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KIN.BR Yearly Shares OutstandingKIN.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
KIN.BR Yearly Total Debt VS Total AssetsKIN.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 1.53, we must say that KIN is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.53, KIN is doing good in the industry, outperforming 65.00% of the companies in the same industry.
KIN has a debt to FCF ratio of 7.71. This is a slightly negative value and a sign of low solvency as KIN would need 7.71 years to pay back of all of its debts.
KIN has a Debt to FCF ratio (7.71) which is in line with its industry peers.
A Debt/Equity ratio of 3.70 is on the high side and indicates that KIN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.70, KIN is doing worse than 70.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.7
Debt/FCF 7.71
Altman-Z 1.53
ROIC/WACC0.98
WACC6.58%
KIN.BR Yearly LT Debt VS Equity VS FCFKIN.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M

2.3 Liquidity

KIN has a Current Ratio of 0.46. This is a bad value and indicates that KIN is not financially healthy enough and could expect problems in meeting its short term obligations.
KIN has a worse Current ratio (0.46) than 77.50% of its industry peers.
A Quick Ratio of 0.43 indicates that KIN may have some problems paying its short term obligations.
The Quick ratio of KIN (0.43) is worse than 77.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.46
Quick Ratio 0.43
KIN.BR Yearly Current Assets VS Current LiabilitesKIN.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

4

3. Growth

3.1 Past

KIN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.42%.
KIN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.01% yearly.
KIN shows a small growth in Revenue. In the last year, the Revenue has grown by 1.05%.
The Revenue has been growing slightly by 4.93% on average over the past years.
EPS 1Y (TTM)-11.42%
EPS 3YN/A
EPS 5Y3.01%
EPS Q2Q%-99.42%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y50.88%
Revenue growth 5Y4.93%
Sales Q2Q%-14.89%

3.2 Future

The Earnings Per Share is expected to grow by 17.04% on average over the next years. This is quite good.
Based on estimates for the next years, KIN will show a small growth in Revenue. The Revenue will grow by 2.15% on average per year.
EPS Next Y-18.47%
EPS Next 2Y10.07%
EPS Next 3Y12.19%
EPS Next 5Y17.04%
Revenue Next Year-3.98%
Revenue Next 2Y3.16%
Revenue Next 3Y4.08%
Revenue Next 5Y2.15%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
KIN.BR Yearly Revenue VS EstimatesKIN.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
KIN.BR Yearly EPS VS EstimatesKIN.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 30.00, the valuation of KIN can be described as expensive.
Based on the Price/Earnings ratio, KIN is valued a bit cheaper than the industry average as 72.50% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 28.47. KIN is around the same levels.
With a Price/Forward Earnings ratio of 15.29, KIN is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of KIN indicates a somewhat cheap valuation: KIN is cheaper than 65.00% of the companies listed in the same industry.
KIN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 92.74.
Industry RankSector Rank
PE 30
Fwd PE 15.29
KIN.BR Price Earnings VS Forward Price EarningsKIN.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KIN is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, KIN is valued a bit cheaper than 77.50% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.06
EV/EBITDA 11.3
KIN.BR Per share dataKIN.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

A more expensive valuation may be justified as KIN's earnings are expected to grow with 12.19% in the coming years.
PEG (NY)N/A
PEG (5Y)9.95
EPS Next 2Y10.07%
EPS Next 3Y12.19%

4

5. Dividend

5.1 Amount

KIN has a Yearly Dividend Yield of 1.02%. Purely for dividend investing, there may be better candidates out there.
KIN's Dividend Yield is a higher than the industry average which is at 2.26.
Compared to an average S&P500 Dividend Yield of 2.28, KIN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 1.02%

5.2 History

On average, the dividend of KIN grows each year by 20.78%, which is quite nice.
Dividend Growth(5Y)20.78%
Div Incr Years1
Div Non Decr Years1
KIN.BR Yearly Dividends per shareKIN.BR Yearly Dividends per shareYearly Dividends per share 2019 2020 2023 2024 0.2 0.4 0.6 0.8

5.3 Sustainability

41.54% of the earnings are spent on dividend by KIN. This is a bit on the high side, but may be sustainable.
KIN's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP41.54%
EPS Next 2Y10.07%
EPS Next 3Y12.19%
KIN.BR Yearly Income VS Free CF VS DividendKIN.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M
KIN.BR Dividend Payout.KIN.BR Dividend Payout, showing the Payout Ratio.KIN.BR Dividend Payout.PayoutRetained Earnings

KINEPOLIS

EBR:KIN (2/5/2025, 11:35:48 AM)

38.1

-0.5 (-1.3%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)10-20 2024-10-20
Earnings (Next)02-20 2025-02-20/amc
Inst Owners18.85%
Inst Owner ChangeN/A
Ins Owners1.8%
Ins Owner ChangeN/A
Market Cap1.04B
Analysts86
Price Target52.8 (38.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.02%
Yearly Dividend0.92
Dividend Growth(5Y)20.78%
DP41.54%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.62%
PT rev (3m)-1.62%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-12.63%
EPS NY rev (3m)-12.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.8%
Revenue NY rev (3m)-2.8%
Valuation
Industry RankSector Rank
PE 30
Fwd PE 15.29
P/S 1.85
P/FCF 10.06
P/OCF 7.43
P/B 5.72
P/tB N/A
EV/EBITDA 11.3
EPS(TTM)1.27
EY3.33%
EPS(NY)2.49
Fwd EY6.54%
FCF(TTM)3.79
FCFY9.94%
OCF(TTM)5.13
OCFY13.46%
SpS20.57
BVpS6.67
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)9.95
Profitability
Industry RankSector Rank
ROA 3.2%
ROE 19.41%
ROCE 8.81%
ROIC 6.48%
ROICexc 6.85%
ROICexgc 8.83%
OM 13.74%
PM (TTM) 6.29%
GM 23.56%
FCFM 18.41%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y0.72%
PM growth 3YN/A
PM growth 5Y-1.43%
GM growth 3YN/A
GM growth 5Y-0.65%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 3.7
Debt/FCF 7.71
Debt/EBITDA 4.22
Cap/Depr 44.37%
Cap/Sales 6.53%
Interest Coverage 3.01
Cash Conversion 87.68%
Profit Quality 292.73%
Current Ratio 0.46
Quick Ratio 0.43
Altman-Z 1.53
F-Score7
WACC6.58%
ROIC/WACC0.98
Cap/Depr(3y)32.78%
Cap/Depr(5y)48.64%
Cap/Sales(3y)5.97%
Cap/Sales(5y)10.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.42%
EPS 3YN/A
EPS 5Y3.01%
EPS Q2Q%-99.42%
EPS Next Y-18.47%
EPS Next 2Y10.07%
EPS Next 3Y12.19%
EPS Next 5Y17.04%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y50.88%
Revenue growth 5Y4.93%
Sales Q2Q%-14.89%
Revenue Next Year-3.98%
Revenue Next 2Y3.16%
Revenue Next 3Y4.08%
Revenue Next 5Y2.15%
EBIT growth 1Y-6.93%
EBIT growth 3YN/A
EBIT growth 5Y5.69%
EBIT Next Year81.02%
EBIT Next 3Y30.65%
EBIT Next 5Y25.76%
FCF growth 1Y-22.26%
FCF growth 3YN/A
FCF growth 5Y31.8%
OCF growth 1Y-6.25%
OCF growth 3YN/A
OCF growth 5Y11.17%